IP Strategy for Life Science Start-ups: Workshop with Dr. Chris Barden
OnlineIn the life sciences industry, IP is everything. Join us for an in-depth look at IP for life sciences start-ups with Dr. Chris Barden, CEO of US/Canadian pharma company Treventis Corp. and a registered U.S. Patent Agent. Dr. Barden will share “lessons learned” navigating the regulatory system in the U.S. and the EU and how he built a robust IP portfolio. At Treventis he leads a team of scientists working on disease-modifying therapeutics against protein misfolding diseases such as Alzheimer’s (the subject of a $370MM partnership with Takeda). Topics covered: When and when NOT to Patent U.S. Clinical Research Regulations Protecting Trade Secrets Leveraging licensing opportunities Tactics and Best Practices About Dr. Chris Barden Chris is a serial entrepreneur and inventor (80+ issued patents) with R&D, operating, dealmaking, and other executive experience in several pharmaceutical, medical device, and diagnostic start-ups. At Treventis, he leads a team of scientists working to design disease-modifying therapeutics against protein misfolding diseases such as Alzheimer’s (the subject of a $370MM partnership with Takeda). In his IP consulting practice, Chris brings a founder’s perspective to the complicated landscape of patent rules and regulations, helping companies understand how to best position their IP for commercial success, […]